Aclaris Therapeutics Gross Profit Growth & History (ACRS)
Aclaris Therapeutics's gross profit was $5.7M for fiscal 2025.
View full Aclaris Therapeutics company overviewAclaris Therapeutics annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.7M | −$10.2M | −63.99% |
| 2024 | 2024-12-31 | $15.9M | −$11.9M | −42.76% |
| 2023 | 2023-12-31 | $27.8M | $2.1M | +8.15% |
| 2022 | 2022-12-31 | $25.7M | $23.7M | +1156.30% |
| 2021 | 2021-12-31 | $2.0M | $699,000 | +51.82% |
| 2020 | 2020-12-31 | $1.3M | $1.2M | +684.30% |
| 2019 | 2019-12-31 | $172,000 | −$3.1M | −94.69% |
| 2018 | 2018-12-31 | $3.2M | $2.8M | +580.88% |
| 2017 | 2017-12-31 | $476,000 | — | — |
Aclaris Therapeutics quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | $149,000 | +11.81% |
| Q1 2026 | 2026-03-31 | $1.6M | $652,000 | +68.70% |
| Q4 2025 | 2025-12-31 | $763,000 | −$7.7M | −91.03% |
| Q3 2025 | 2025-09-30 | $2.8M | −$931,000 | −25.22% |
| Q2 2025 | 2025-06-30 | $1.3M | −$880,000 | −41.08% |
| Q1 2025 | 2025-03-31 | $949,000 | −$640,000 | −40.28% |
| Q4 2024 | 2024-12-31 | $8.5M | −$8.3M | −49.51% |
| Q3 2024 | 2024-09-30 | $3.7M | −$4.7M | −56.22% |
| Q2 2024 | 2024-06-30 | $2.1M | $1.3M | +159.01% |
| Q1 2024 | 2024-03-31 | $1.6M | −$131,000 | −7.62% |
| Q4 2023 | 2023-12-31 | $16.8M | $10.0M | +144.98% |
| Q3 2023 | 2023-09-30 | $8.4M | −$9.7M | −53.39% |
| Q2 2023 | 2023-06-30 | $827,000 | $367,000 | +79.78% |
| Q1 2023 | 2023-03-31 | $1.7M | $1.4M | +477.18% |
| Q4 2022 | 2022-12-31 | $6.9M | $6.5M | +1853.41% |
| Q3 2022 | 2022-09-30 | $18.1M | $17.5M | +3131.25% |
| Q2 2022 | 2022-06-30 | $460,000 | −$101,000 | −18.00% |
| Q1 2022 | 2022-03-31 | $298,000 | −$277,000 | −48.17% |
| Q4 2021 | 2021-12-31 | $352,000 | $58,000 | +19.73% |
| Q3 2021 | 2021-09-30 | $560,000 | $300,000 | +115.38% |
| Q2 2021 | 2021-06-30 | $561,000 | −$96,000 | −14.61% |
| Q1 2021 | 2021-03-31 | $575,000 | $437,000 | +316.67% |
| Q4 2020 | 2020-12-31 | $294,000 | $227,000 | +338.81% |
| Q3 2020 | 2020-09-30 | $260,000 | $103,000 | +65.61% |
| Q2 2020 | 2020-06-30 | $657,000 | $765,000 | — |
| Q1 2020 | 2020-03-31 | $138,000 | $82,000 | +146.43% |
| Q4 2019 | 2019-12-31 | $67,000 | −$93,000 | −58.13% |
| Q3 2019 | 2019-09-30 | $157,000 | −$278,000 | −63.91% |
| Q2 2019 | 2019-06-30 | −$108,000 | −$2.6M | — |
| Q1 2019 | 2019-03-31 | $56,000 | −$95,000 | −62.91% |
| Q4 2018 | 2018-12-31 | $160,000 | −$85,000 | −34.69% |
| Q3 2018 | 2018-09-30 | $435,000 | $204,000 | +88.31% |
| Q2 2018 | 2018-06-30 | $2.5M | — | — |
| Q1 2018 | 2018-03-31 | $151,000 | — | — |
| Q4 2017 | 2017-12-31 | $245,000 | — | — |
| Q3 2017 | 2017-09-30 | $231,000 | — | — |
Aclaris Therapeutics gross profit trends
Over the last five fiscal years, Aclaris Therapeutics's gross profit increased from $1.3M to $5.7M, a change of $4.4M. The latest reported quarter, Q2 2026, shows $1.4M.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aclaris Therapeutics source filings ↗